In many fire departments across the United States, opioid overdose calls now represent one of the most frequent EMS responses crews make. More than 80,000 Americans died of opioid overdose in a recent reporting year — a figure that exceeds U.S. traffic fatalities. Behind each statistic is a 911 call where a firefighter or paramedic had minutes to reverse a potentially fatal respiratory arrest with naloxone and skilled airway management.
The opioid crisis has fundamentally changed what fire service EMS looks like — from the medications carried on apparatus, to training priorities, to crew safety protocols, to the expanding role of community paramedicine in overdose follow-up. This guide explains exactly what happens from the moment a crew is dispatched to an overdose call through patient handoff — and the clinical and operational decisions that determine whether the patient survives.
30–90 minDuration of naloxone action — shorter than many synthetic opioids, creating re-narcotization risk
2 mgTypical initial naloxone dose in current fentanyl-era protocols — 5× the traditional heroin-era dose
Recognizing an Opioid Overdose: The Toxidrome
Opioid overdose produces a recognizable clinical pattern — the "opioid toxidrome" — that allows trained responders to identify it quickly and begin treatment before lab confirmation is possible. The classic triad is:
Sign
What It Looks Like
Mechanism
Pinpoint (miotic) pupils
Pupils extremely small — as small as a pinhole — even in low light conditions
Opioids stimulate parasympathetic pathways causing maximum pupil constriction
Respiratory depression
Fewer than 10 breaths/minute; irregular breathing; absent breathing (apnea); gurgling or snoring sounds from tongue obstruction
Opioids bind to μ-receptors in the brainstem respiratory center, suppressing the drive to breathe
Decreased consciousness
Unresponsive to voice or sternal rub; deep sedation; complete unconsciousness
CNS depression from opioid receptor binding in brain
Mixed-substance overdoses — combining opioids with alcohol, benzodiazepines, or stimulants — may present atypically. Stimulant-opioid combinations (speedballing) may show less pronounced respiratory depression initially. Benzodiazepine combination overdoses may not respond adequately to naloxone alone. Assessment should always include blood glucose check — hypoglycemia mimics altered consciousness and requires different treatment.
Scene Response: Step by Step
SCENE SAFE
Scene safety assessment before patient contact
Overdose scenes can present multiple safety hazards: other individuals who may be intoxicated or combative; drug paraphernalia (needles — use PPE); potential for visible powder (fentanyl — do not disturb, use N95); pets; weapons. Law enforcement co-response is common in many jurisdictions. Approach scene from upwind if any powdery substance is visible. Don nitrile gloves before contact.
Check responsiveness (voice, sternal rub). Open airway — head-tilt chin-lift or jaw thrust. Assess breathing rate, depth, and adequacy. Check radial and carotid pulse. Pupils: miotic (pinpoint) is the hallmark sign. Skin color and temperature. SpO₂ if available. Time from assessment to naloxone administration should be under 60 seconds for apneic patient.
AIRWAY
Airway management and ventilation if breathing is inadequate
For apneic or severely bradypneic patients: position patient, insert nasopharyngeal airway (NPA) to maintain airway, and begin BVM ventilation with oxygen before or simultaneously with naloxone administration. Providing 30–60 seconds of ventilation before naloxone in an apneic patient improves brain oxygenation and may improve outcomes. Do not delay naloxone while waiting for airway equipment to be prepared.
NALOX
Naloxone administration — route and dose based on protocol
Intranasal (IN) delivery via mucosal atomizer is the most common prehospital route — no needle, fast, and effective. Standard fentanyl-era initial dose: 2 mg IN divided between nostrils. IM injection (lateral thigh or deltoid) has faster absorption than IN. IV/IO provides fastest onset but requires access. Reassess at 2–3 minutes — if no response, repeat dose. Continue until adequate respiratory function is restored.
MONITOR
Post-reversal monitoring and reassessment
Continuous SpO₂ and respiratory rate monitoring after reversal. Cardiac monitoring — opioid overdose and subsequent naloxone-precipitated withdrawal can cause dysrhythmias. Glucose check to rule out co-occurring hypoglycemia. Temperature — prolonged unconsciousness can cause hypothermia. Document exact times of all interventions and patient responses. Prepare for transport.
TRANS
Transport and hospital notification
All patients who received naloxone for opioid overdose should be transported — re-narcotization risk requires monitored observation beyond naloxone's duration. Pre-notify ED with patient status, substances suspected, naloxone doses given and response, current vitals. If patient refuses transport, document thoroughly and provide naloxone kit and harm reduction resources.
Naloxone Dosing: The Fentanyl Era Has Changed Everything
0.4mg
Traditional Dose (Heroin Era)
Often insufficient for synthetic opioids; may partially reverse but inadequate respiratory recovery
2mg
Current Initial Dose (Fentanyl Era)
Standard first dose for suspected fentanyl overdose in most current EMS protocols; repeat every 2–3 min if no response
8–10mg
Refractory High-Dose Protocols
Some protocols allow up to 10 mg for carfentanil or no-response presentations; confirm with local medical director guidance
Route
Onset
Considerations
Intranasal (IN)
3–5 min
No needle; easy to administer; divided dose between nostrils increases absorption area; affected by nasal congestion or cocaine insufflation damage
Intramuscular (IM)
5–10 min
Reliable absorption; lateral thigh; used when IN access is compromised; needle required
Intravenous (IV)
<2 min
Fastest onset; titrateable; requires IV access first; risk of precipitating acute withdrawal and agitation if given as bolus too fast
Intraosseous (IO)
<2 min
Used when IV access fails; same speed as IV; bone marrow delivery; painful if patient regains consciousness
Crew Safety: Fentanyl Exposure Reality vs. Myth
Concerns about fentanyl exposure during overdose response are widespread in the fire and EMS community, partly due to high-profile media reports. The evidence-based guidance from ACEP, NAEMSP, the American College of Medical Toxicology, and other professional organizations provides important clarity:
Claim
Evidence-Based Reality
Skin contact with fentanyl on a patient will cause crew overdose
FALSE — transdermal absorption from incidental skin contact is not a clinically significant exposure route for first responders; intact skin is an effective barrier for the short contact duration of patient care
Inhaling air near a fentanyl overdose patient is dangerous
FALSE — ambient air near an overdose patient does not contain aerosolized fentanyl at dangerous concentrations; the patient did not inhale themselves into overdose from ambient air
Visible white powder at a scene presents airborne inhalation risk
TRUE — undisturbed powder should not be handled; N95 or P100 respiratory protection indicated if powder disturbance is possible; do not use fans or PPV ventilation near visible powder
Standard PPE (nitrile gloves + face protection) is adequate for routine overdose calls
TRUE — nitrile gloves, eye protection, and face protection provide adequate protection for standard patient contact; change gloves and wash hands after
Any crew member with symptoms after overdose scene should receive naloxone
TRUE — if any crew member develops sedation, slowed breathing, or pinpoint pupils at any point, administer naloxone and treat as a patient
After the Call: Harm Reduction and Follow-Up
The moment after a naloxone reversal — when a patient is conscious but still at a scene — is a brief and often underutilized opportunity for harm reduction. EMS providers who connect patients with resources in this moment have been shown to increase treatment engagement in several study populations:
Offer a naloxone kit before transport or after refusal — many departments carry extra kits for distribution; bystander naloxone saves lives
Provide treatment referral information — brief motivational contact at the scene of an overdose has documented efficacy for treatment engagement
Document findings thoroughly in PCR — pattern data at the agency level drives public health response and community paramedicine program design
Request peer support or community health worker follow-up if your agency has CP capabilities — post-overdose 24–72 hour visits significantly improve treatment engagement
Communicate observed drug supply changes to supervisors — new substances, color changes, or unusual overdose presentations are syndromic surveillance data
Access your agency's peer support program after difficult calls — repeated overdose scenes, especially pediatric cases, are a significant contributor to EMS provider burnout and PTSD
For the full context of EMS operations in the fire service — including cardiac arrest response, trauma operations, team roles, and the future of community paramedicine — see our complete guide to firefighter–paramedics and fire department EMS. For operational reference tools relevant to EMS response, including drug reference and hazmat first-action guides for clandestine lab and chemical overdose scenes, see the AllFirefighter Hazmat Hub and the Tools section.
The classic opioid overdose triad — also called the 'opioid toxidrome' — consists of three observable signs: pinpoint (miotic) pupils, respiratory depression or apnea (absence of breathing), and decreased level of consciousness ranging from deep sedation to complete unresponsiveness. A person in opioid overdose may be unresponsive to voice or sternal rub, breathing very slowly (fewer than 10 breaths per minute) or not at all, with skin that may be pale, cyanotic (blue-tinged), or clammy. Gurgling or 'death rattle' breathing sounds indicate airway obstruction from a relaxed tongue and throat. Not all three signs are always present, particularly with mixed-substance overdoses — any two should prompt immediate treatment.
Traditional naloxone dosing (0.4 mg) was developed for heroin and prescription opioids. The illicit fentanyl now driving U.S. overdose deaths is 50–100 times more potent than morphine, and carfentanil (increasingly detected in the drug supply) is approximately 10,000 times more potent. These potencies overwhelm standard doses. Most EMS systems now initiate with 2 mg intranasal (IN) or intramuscular (IM) for suspected fentanyl overdose, with rapid repeat dosing every 2–3 minutes until respiratory function is restored. Some protocols allow up to 8–10 mg in refractory cases. The goal is adequate respiratory function — not full reversal to alert and agitated, which can trigger combative behavior and cause the patient to leave the scene before residual opioid effects wear off.
Re-narcotization occurs when naloxone's effects wear off before the opioid it reversed has been metabolized. Naloxone has a duration of action of approximately 30–90 minutes depending on the dose and route of administration. Fentanyl and other synthetic opioids can have much longer durations — especially in the context of illicit formulations that may include extended-release coatings or high-dose unknowns. A patient who appears fully recovered after naloxone may slip back into respiratory depression 30–60 minutes later as the naloxone wears off. This is why transport to a hospital for monitoring is strongly recommended even for patients who fully recover with naloxone on scene. EMS protocols typically require a minimum 4-hour monitoring period for synthetic opioid overdoses.
Transdermal absorption through intact skin from incidental contact during patient care presents minimal overdose risk to first responders according to ACEP, NAEMSP, and other medical organizations. The primary pathway for clinically significant fentanyl exposure is inhalation of airborne powder. Standard nitrile gloves and face protection (surgical or N95 mask) are adequate for routine patient contact. Responders should not touch their face with potentially contaminated gloves, should change gloves and wash hands after contact, and should avoid any situation involving visible white powder or aerosol without additional respiratory protection. Any provider who experiences symptoms — dizziness, sedation, pinpoint pupils, slowed breathing — should be treated as a patient immediately with naloxone administered.
A competent adult patient has the legal right to refuse transport and medical care. However, a patient who has just received naloxone is at significant risk of re-narcotization once the naloxone wears off. EMS providers should clearly explain this risk to the patient, document the explanation and the refusal thoroughly in the PCR (prehospital care report), offer harm reduction resources (naloxone kit, treatment referral), and ensure law enforcement or another responsible party is present if possible. Some systems have implemented 'against medical advice with follow-up' protocols where community health workers or peer support specialists make contact with the patient within hours of the incident. If there is any question about the patient's decision-making capacity (from residual intoxication), transport should be pursued.
Community paramedicine and mobile integrated health programs are increasingly being deployed as proactive tools in the opioid crisis. Programs vary by jurisdiction but common models include: LEADS (Law Enforcement Assisted Diversion) co-response where paramedics or community health workers respond alongside police to overdose calls and offer immediate treatment linkage; post-overdose follow-up visits where CP paramedics visit overdose survivors within 24–72 hours to offer treatment resources and naloxone kits; frequent-utilizer programs addressing the repeat 911 caller population with case management; and hospital-to-home transition programs connecting post-overdose hospital patients with community support. Evidence from programs in cities including Gloucester, MA and Boston shows significant reductions in repeat overdose 911 calls among patients enrolled in CP follow-up programs.
